Literature DB >> 25545261

Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers.

Chonlaphat Sukasem1,2, Chalirmporn Atasilp1,2, Pichai Chansriwong3, Montri Chamnanphon1,2, Apichaya Puangpetch1,2, Ekapob Sirachainan3.   

Abstract

BACKGROUND: UGT1A1 is a polymorphic enzyme that has been associated with irinotecan drug metabolisms. We developed a pyrosequencing method to detect allele frequency and genotype of UGT1A1 polymorphisms (UGT1A1*28 and UGT1A1*6) in Thai colorectal cancer patients.
METHOD: A pyrosequencing method was designed to determine UGT1A1 genetic polymorphisms including UGT1A1*28 (A[TA]7TAA) and UGT1A1*6 (211G>A) in 91 Thai colorectal cancers. RESULT: Genotyping by the pyrosequencing technique was 100% concordant with capillary electrophoresis sequencing. The allele frequencies for UGT1A1 genetic polymorphisms were *1/*1 (54.95%), *1/*6 (13.19%), *1/*28 (25.27%), *28/*6 (4.40%), and *28/*28 (2.20%). No homozygous mutation UGT1A1*6 was found in our population.
CONCLUSIONS: We developed a rapid, reliable, more cost-effective, and simple assay to detect UGT1A1 genetic polymorphisms in routine practice before initiating irinotecan therapy. The UGT1A1*28 and UGT1A1*6 alleles were found to be similar in the Asian populations.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  SNP; Thai; UGT1A1; genetic polymorphisms; pyrosequencing

Mesh:

Substances:

Year:  2014        PMID: 25545261      PMCID: PMC6807135          DOI: 10.1002/jcla.21820

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  29 in total

Review 1.  Inherited disorders of bilirubin metabolism.

Authors:  Piter Jabik Bosma
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

2.  Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.

Authors:  Cynthia Sung; Pui Ling Lee; Liesbet L Tan; Dorothy S L Toh
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

3.  Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.

Authors:  Sonia Rodríguez-Nóvoa; Luz Martín-Carbonero; Pablo Barreiro; Gema González-Pardo; Inmaculada Jiménez-Nácher; Juan González-Lahoz; Vincent Soriano
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

4.  Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.

Authors:  Jung-Woo Bae; Chang-Ik Choi; Jin-Hee Lee; Choon-Gon Jang; Myeon-Woo Chung; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2010-09-24       Impact factor: 2.953

5.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

Authors:  L Iyer; S Das; L Janisch; M Wen; J Ramírez; T Karrison; G F Fleming; E E Vokes; R L Schilsky; M J Ratain
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

6.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

7.  Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.

Authors:  Koichi Hirose; Chihiro Kozu; Koshiro Yamashita; Eiji Maruo; Mizuho Kitamura; Junichi Hasegawa; Kei Omoda; Teruo Murakami; Yorinobu Maeda
Journal:  Oncol Lett       Date:  2011-12-22       Impact factor: 2.967

8.  Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Authors:  Hironobu Minami; Kimie Sai; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kazuhiro Suzuki; Nahoko Kaniwa; Jun-ichi Sawada; Tetsuya Hamaguchi; Noboru Yamamoto; Kuniaki Shirao; Yasuhide Yamada; Hironobu Ohmatsu; Kaoru Kubota; Teruhiko Yoshida; Atsushi Ohtsu; Nagahiro Saijo
Journal:  Pharmacogenet Genomics       Date:  2007-07       Impact factor: 2.089

9.  Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.

Authors:  Jian-Ming Xu; Yan Wang; Fei-Jiao Ge; Li Lin; Ze-Yuan Liu; Manish R Sharma
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

10.  Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.

Authors:  Sung-Hao Huang; Yee Chao; Ying-Ying Wu; Jiing-Chyuan Luo; Chien-Hui Kao; Sang-Hue Yen; Chung-Pin Li
Journal:  Tumori       Date:  2011 Mar-Apr
View more
  11 in total

Review 1.  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors:  Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

2.  Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia.

Authors:  Thitipon Yaowaluk; Vorapun Senanarong; Chanin Limwongse; Rasda Boonprasert; Duangkamon Bunditvorapoom; Supannee Kaewsutthi; Pornpimol Kijsanayotin
Journal:  Eur J Clin Pharmacol       Date:  2022-05-28       Impact factor: 3.064

3.  "Gilbert's-like" syndrome as part of a spectrum of persistent unconjugated hyperbilirubinemia in post-chronic hepatitis patients.

Authors:  Jin Ye; Lianlian Cui; Yingqiao Zhou; Ying Huang; Omar Banafa; Xiaohua Hou; Zhen Ding; Rong Lin
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

4.  Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?

Authors:  Tristan M Sissung; Roberto H Barbier; Douglas K Price; Teri M Plona; Kristen M Pike; Stephanie D Mellott; Ryan N Baugher; Gordon R Whiteley; Daniel R Soppet; David Venzon; Arlene Berman; Arun Rajan; Giuseppe Giaccone; Paul Meltzer; William D Figg
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

5.  The reference liver-CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype.

Authors:  Mateusz Kurzawski; Sylwia Szeląg-Pieniek; Joanna Łapczuk-Romańska; Maciej Wrzesiński; Stefan Oswald; Marek Droździk
Journal:  Pharmacol Rep       Date:  2021-11-06       Impact factor: 3.024

6.  Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population.

Authors:  Chalirmporn Atasilp; Janjira Kanjanapipak; Jaratdao Vichayaprasertkul; Pimonpan Jinda; Rawiporn Tiyasirichokchai; Pornpen Srisawasdi; Chatchay Prempunpong; Monpat Chamnanphon; Apichaya Puangpetch; Natchaya Vanwong; Suwit Klongthalay; Thawinee Jantararoungtong; Chonlaphat Sukasem
Journal:  BMC Pediatr       Date:  2022-05-02       Impact factor: 2.567

7.  Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.

Authors:  Sadeep Medhasi; Ekawat Pasomsub; Natchaya Vanwong; Nattawat Ngamsamut; Apichaya Puangpetch; Montri Chamnanphon; Yaowaluck Hongkaew; Penkhae Limsila; Darawan Pinthong; Chonlaphat Sukasem
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-13       Impact factor: 2.570

8.  Haplotype-Contained PCR Products Analysis by Sequencing with Selective Restriction of Primer Extension.

Authors:  Liu Wang; Pengfeng Xiao
Journal:  Biomed Res Int       Date:  2017-12-10       Impact factor: 3.411

9.  Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.

Authors:  Chalirmporn Atasilp; Phichai Chansriwong; Ekaphop Sirachainan; Thanyanan Reungwetwattana; Suwannee Sirilerttrakul; Monpat Chamnanphon; Apichaya Puangpetch; Chonlaphat Sukasem
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

10.  Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy.

Authors:  Daniela Poblete; Fernando Bernal; Gabriel Llull; Sebastian Archiles; Patricia Vasquez; Leonardo Chanqueo; Nicole Soto; María A Lavanderos; Luis A Quiñones; Nelson M Varela
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.